anb019
mAbexperimental
Clinical trial activity
8 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
8
Phase 3
2
Phase 4
0
Earliest trial started Sep 30, 2018 (NCT03619902)
Timeline
Indications
Mechanism of action
- IL36 receptorANTAGONIST
IL36 receptor antagonist
- IL36 receptorINHIBITOR
IL36 receptor inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650441 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05366855 | Phase 3 | Apr 21, 2022 | AnaptysBio, Inc. |
| NCT05352893 | Phase 3 | Apr 14, 2022 | AnaptysBio, Inc. |
| NCT04856930 | Phase 2 | May 31, 2021 | AnaptysBio, Inc. |
| NCT04856917 | Phase 2 | May 15, 2021 | AnaptysBio, Inc. |
| NCT04697056 | Phase 2 | Jan 25, 2021 | AnaptysBio, Inc. |
| NCT04697069 | Phase 2 | Jan 22, 2021 | AnaptysBio, Inc. |
| NCT03619902 | Phase 2 | Sep 30, 2018 | AnaptysBio, Inc. |
| NCT03633396 | Phase 2 | Sep 30, 2018 | AnaptysBio, Inc. |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AnaptysBio, Inc. | For profit | 8 | 8 | 2 | 2018 |
1 organizations
Page 1 / 1